GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (LIM:BSX) » Definitions » Cyclically Adjusted PS Ratio

Boston Scientific (LIM:BSX) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Boston Scientific Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Boston Scientific Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Boston Scientific's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Cyclically Adjusted PS Ratio Chart

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.12 5.51 5.89 5.86 6.85

Boston Scientific Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.18 6.55 6.29 6.85 -

Competitive Comparison of Boston Scientific's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.



Boston Scientific Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.606/129.4194*129.4194
=2.606

Current CPI (Dec. 2023) = 129.4194.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.315 99.695 1.707
201406 1.393 100.560 1.793
201409 1.370 100.428 1.765
201412 1.422 99.070 1.858
201503 1.326 99.621 1.723
201506 1.353 100.684 1.739
201509 1.405 100.392 1.811
201512 1.470 99.792 1.906
201603 1.434 100.470 1.847
201606 1.566 101.688 1.993
201609 1.526 101.861 1.939
201612 1.583 101.863 2.011
201703 1.554 102.862 1.955
201706 1.622 103.349 2.031
201709 1.594 104.136 1.981
201712 1.726 104.011 2.148
201803 1.703 105.290 2.093
201806 1.780 106.317 2.167
201809 1.705 106.507 2.072
201812 1.821 105.998 2.223
201903 1.770 107.251 2.136
201906 1.868 108.070 2.237
201909 1.917 108.329 2.290
201912 2.055 108.420 2.453
202003 1.799 108.902 2.138
202006 1.420 108.767 1.690
202009 1.858 109.815 2.190
202012 1.897 109.897 2.234
202103 1.923 111.754 2.227
202106 2.148 114.631 2.425
202109 2.042 115.734 2.283
202112 2.177 117.630 2.395
202203 2.104 121.301 2.245
202206 2.269 125.017 2.349
202209 2.217 125.227 2.291
202212 2.268 125.222 2.344
202303 2.371 127.348 2.410
202306 2.518 128.729 2.532
202309 2.467 129.860 2.459
202312 2.606 129.419 2.606

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Boston Scientific  (LIM:BSX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Boston Scientific Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (LIM:BSX) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.